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Abstract
Background: Prion-based diseases are incurable transmissible neurodegenerative disorders affecting animals and humans.
Methodology/Principal Findings: Here we report the discovery of the in vivo antiprion activity of Guanabenz (GA), an
agonist of a2-adrenergic receptors routinely used in human medicine as an antihypertensive drug. We isolated GA in a
screen for drugs active in vivo against two different yeast prions using a previously described yeast-based two steps assay.
GA was then shown to promote ovine PrP
Sc clearance in a cell-based assay. These effects are very specific as evidenced by
the lack of activity of some GA analogues that we generated. GA antiprion activity does not involve its agonist activity on
a2-adrenergic receptors as other chemically close anti-hypertensive agents possessing related mechanism of action were
found inactive against prions. Finally, GA showed activity in a transgenic mouse-based in vivo assay for ovine prion
propagation, prolonging slightly but significantly the survival of treated animals.
Conclusion/Significance: GA thus adds to the short list of compounds active in vivo in animal models for the treatment of
prion-based diseases. Because it has been administrated for many years to treat hypertension on a daily basis, without
major side-effects, our results suggest that it could be evaluated in human as a potential treatment for prion-based diseases.
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Introduction
Prion-based diseases are transmissible and invariably fatal
neurodegenerative disorders for which no treatment is currently
available [1]. Among these diseases are Creutzfeldt-Jakob disease
(CJD) in humans, bovine spongiform encephalopathies in cattle
and scrapie in sheep and goat. These diseases are associated with
neuronal cell death which leads to characteristic ‘‘spongiform’’
vacuolation of the brain. According to the ‘‘protein-only’’
hypothesis, prions are solely composed of an abnormal form
(PrP
Sc) of the PrP protein (PrP
C), a glycosyl-phosphatidyl inositol
(GPI) anchored protein normally expressed at the surface of a
number of cell types including in particular neurons. Transmis-
sibility necessitates the conversion of host PrP
C by exogenous
PrP
Sc. PrP
Sc isoform displays a pronounced protease resistance,
shows an increase in b-sheet structures and forms aggregates.
Based on the assumption that PrP
Sc corresponds to (or at least is
part of) the pathogenic entity, various approaches aiming at
reducing PrP
Sc or PrP
C levels for the development of prion disease
therapies are currently explored (comprehensively reviewed in
[1]). Indeed, recent results showed that depleting PrP
C from
neurons of prion-infected mice in which the Prnp gene (encoding
PrP protein) can be turned off, not only prevented progression of
clinical disease, but also reversed spongiosis and early cognitive
deficits and neurophysiological dysfunction [2,3]. Thus approach-
es leading to reduction of endogenous PrP
C or PrP
Sc levels may
well be effective after the appearance of symptoms. Among these
approaches are passive or active immunisations [4,5] whereas
others aim at the identification of pharmacological compounds or
of peptide aptamers [6] promoting PrP
Sc clearance. Some of these
approaches are based on the use of cell-free systems [7–10]
whereas others are based on the use of mammalian cells
chronically infected with prions ([11–14], reviewed in [15]). In
most of these assays, drugs efficiency is monitored by their effects
on proteinase K resistant-PrP
Sc accumulation and sometimes by
titration of infectivity levels. All these assays are time and money
consuming, in particular because experiments have to be carried
out in highly secured-laboratories. For this reason, we developed a
rapid and economical budding yeast (Saccharomyces cerevisiae)-based
two steps assay to screen for antiprion molecules [16,17].
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1981Indeed, since 1994 [18] it is known that budding yeast contains
several proteins behaving like prions (reviewed in [19]) and several
simple reporter systems have been developed to investigate their
behavior. In the first step of our assay, molecules from various
chemical libraries were isolated on the basis of their in vivo activity
against the [PSI
+] yeast prion. In the second step, the active hits
were tested against [URE3], a second yeast prion unrelated to
[PSI
+]. Both steps are based on the use of a white and red colony
coloration system: prion-containing yeast cells ([PSI
+] or [URE3]
cells) form white colonies on rich medium (YPD) whereas cells in
which the prion phenotype is cured ([psi
2]o r[ ure3-0] cells) grow as
red colonies. Our initial assumption that prion-controlling
mechanisms could be conserved from yeast to mammals was
confirmed when most of the active compounds isolated in the
yeast-based assay turned out to be also active to promote PrP
Sc
clearance in three different mammalian cell-based assays [16,20].
A number of chemical libraries have been screened using this
method including the Prestwick Chemical LibraryH, a collection of
compounds at least in phase II of clinical trials. This library is
composed of 880 molecules, among which 90% are marketed
drugs and 10% bioactive alkaloids or related substances, thus
representing a high degree of drug-likeness. Screening of this drug
library followed the ‘‘SOSA Approach’’ consisting of submitting to
the screening target only a limited number of highly diverse drugs
for which bioavailability and toxicity studies have already been
performed and which have proven their usefulness in human [21].
The positive hits can then be used as starting points for drug
optimization programs. However, if the initial hit(s) has sufficient
affinity for the target, it can be immediately tested in patients.
Here we report the identification, from this library, of in vivo
activity of Guanabenz acetate against both yeast and mammalian
prions.
Results
Guanabenz (GA) and Tacrine (TA) are active against yeast
prions
Among others, the Prestwick Chemical LibraryH was screened
using the yeast-based assay. As expected, we found Chlorprom-
azine (CPZ) and Quinacrine (QC), which are present in the
Prestwick library, to be weakly active against yeast prions (Figure
S1), as previously observed [16]. Eleven other compounds of the
Prestwick Chemical LibraryH also showed weak effects (data not
shown). Among all the other drugs, only two presented a strong
activity against yeast prions: Tacrine (TA), a cholinesterase
inhibitor in clinic for the symptomatic treatment of memory loss
in Alzheimer’s disease [22], and Guanabenz acetate (GA), an
agonist of a2-adrenergic receptor used in the treatment of
hypertension [23]. TA and GA were both active against [PSI
+]
prion (Figure 1 panels a and b) and were then evaluated against
the [URE3] prion and found to be also active (Figure 1b).
Hydroxy Tacrine (hTA) was also found to be moderately active
against [PSI
+] prion (Figure S2, panel a).
GA efficiently promotes ovine PrP
Sc clearance in an ex
vivo cell-based assay
The three compounds were then tested for their ability to
promote PrP
Sc clearance in the mammalian MovS6 cell-based
assay [14]. MovS6 cells correspond to a murine peripheral
neuroglial cell line expressing ovine PrP gene (VRQ allele) under
the control of its endogenous promoter. These cells are permissive
to the 127S sheep scrapie agent [24]. Scrapie-infected MovS6 cells
do not have any limitation in term of stability of infection (they
remain stably infected even after long-term storage in liquid
nitrogen) and accumulate high levels of both PrP
Sc and infectivity
[14]. This assay was therefore chosen among other cell-based
assays in order to test molecules in more stringent conditions and
maybe avoid subsequent disappointing results in vivo [25,26]. In
addition and contrary to other cell-based assays, in the MovS6
cell-based assay cells already reached confluence when the drugs
were added. A 6-days treatment with either TA or hTA in the 0 to
20 mM range of concentration did not prevent PrP
Sc accumulation
in chronically-infected MovS6 cells as shown by Western blot
analysis (Figure 2, panel a and Figure S2, panel b) suggesting
that both molecules may be inactive against these mammalian
prions in the tested range of concentration. In contrast, using the
same conditions of treatment and a even lower range of
concentration (0 to 10 mM), GA decreased PrP
Sc amount in the
MovS6 cell cultures to levels barely detectable by Western blot
(Figure 2, panel b, upper gel). By testing different concentrations,
a dose-dependent antiprion effect was observed indicating that GA
is active in the low micromolar range against PrP
Sc in the MovS6
cell-based system (Figure 2, panel b, upper gel). In the same set of
experiments we followed by Western blot analysis the level of total
PrP
C in non-infected MovS6 cells to determine if GA has any
effect on the basal level of PrP expression in MovS6 cells, which
could indirectly affect PrP
Sc accumulation (Figure 2 panel b,
bottom). As PrP level remained unchanged, we conclude that GA
does not act by decreasing the steady state level of PrP.
GA does not act directly on PrP
Sc aggregates
We next examined whether GA would be able to act directly on
PrP
Sc aggregates, as previously described for other drugs such as
Congo red or iododoxorubicin [27–29]. For this purpose, we
incubated protein lysates from untreated infected MovS6 cells for
five hours at 25uC without or with 100 mM of GA and then
submitted them to proteinase K assay. As shown in Figure 2c,a t
100 mM GA (which represents about 20 times the active
concentration of GA in cell culture), the level of PrP
Sc did not
change significantly meaning that this molecule does not exert any
direct effect against PrP
Sc aggregates. In addition, GA was unable
to inhibit the in vitro transconversion of PrP
C in PrP
Sc in a Protein
Misfolded Cyclic Amplification assay (PMCA) and did not directly
interact with PrP (Tribouillard-Tanvier et al. submitted), further
confirming that this drug is probably not acting in cis on PrP.
Activity of chemical derivatives of GA
Chemical derivatives of GA were then synthesized and tested
against both yeast and mammalian prions using respectively the
yeast-based and MovS6-based assays described above. As shown
in Figure 3a, suppressing only one of the two chlorines (PSI 136)
or even replacing it by fluorine (GAi) or by bromide (PSI 137) was
sufficient to lead to a complete loss of activity in both assays. In
contrast, adding supplementary chlorine onto GA (GAh) increased
its activity against both [PSI
+] and [URE3] and in the MovS6 cell-
based assay, highlighting the importance of these two chlorines.
This also confirmed the specificity of the screening method.
Interestingly, activity of the various molecules in the MovS6 cell-
based assay parallels their activity against yeast prions: GAi was
also found inactive and GAh slightly more active than GA (bottom
right panels).
Antiprion activity of GA may not involve its agonist
activity on a2-adrenergic receptors
To test if the antiprion activity of GA observed in MovS6 cells
could be due to its agonist activity on a2-adrenergic receptors
(which is responsible of its antihypertensive action), we tested the
New Indication for Guanabenz
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is pharmacologically and chemically very close to GA. Indeed CD
is also an agonist of a2-adrenergic receptor used in clinic as an
antihypertensive agent [30]. CD did not exhibit any antiprion
activity in yeast nor in MovS6 cells (Figure 3b), suggesting that
the antiprion activity of GA does probably not involve the same
mechanism as the one linked to its antihypertensive action. The
same result was obtained when using a variety of agonists or
antagonists of a1- or a2-adrenergic receptors like Cirazoline (an
agonist of a1- or a2-adrenergic receptors), Rilmenidine (an agonist
of imidazoline I1 receptors) or Efaroxan (an antagonist of a2-
adrenergic receptor) (Figure 3b). In addition, the antiprion
activity of GA in S. cerevisiae cannot be due to its agonist activity on
a2-adrenergic receptors since yeast does not contain adrenergic
receptors. Taken together, these results suggest that the antiprion
activity of GA does not use the cellular pathway leading to its
antihypertensive effect.
Activity of GA in a mouse model for prion-based disease
We finally evaluated the in vivo effect of GA on mammalian
prion using a ‘‘rapid’’ mouse model for prion-based disease [29].
Tg338 mice overexpressing ovine PrP (VRQ allele) were
intraperitoneally inoculated with a high dose of the 127S strain.
We first examined whether repeated intraperitoneal injections of
GA would be toxic for mice. Acute toxicity was observed over
40 mg/kg of GA. We thus chose not to exceed the dose of 20 mg/
Figure 1. Guanabenz and Tacrine are active against yeast prions. a. An aliquot of an overnight culture a [PSI+] Strg6 strain (which grows as
white colonies) was spread on Petri plates containing rich YPD (as indicated in the Materials and Methods section). Small filters (similar to the ones
used for antibiograms) were then placed on the agar surface and individual compounds from the Prestwick chemical libraryH (5 ml of 2 mg/ml
solutions) were applied to each filter, except for the top left filter where DMSO, the compounds vehicle was added (negative control) and for the
bottom right filter where 5 ml of a 300 mM GuHCl solution in DMSO was added (positive control). The Petri plates were then incubated three days at
25uC. When a compound was active against [PSI+], a halo of red colonies appeared around the filter where it was spotted. Petri plates where
Guanabenz (GA, left) and Tacrine (TA, right) were spotted are shown. The molecular structures of Guanabenz and of Tacrine are depicted on the top
of the Petri plates. The red halos corresponding to GA- or TA-cured cells are indicated by arrows. Brown halos correspond to toxic compounds (see
Materials and Methods). b. GA and TA were then tested against [URE3] prion using SB34 strain and the same kind of assay. As confirmations GA
and TA were retested against [PSI+] prion. The same quantity (5 ml of a 5 mM solution) of GA (left) or TA (right) was applied on the filters thus
allowing direct comparison of effect of both molecules on the two yeast prions.
doi:10.1371/journal.pone.0001981.g001
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avoid direct interaction between inoculum and the drug), tg338
mice were intraperitoneally treated with GA until the apparition of
clinical signs in solvent-treated mice. GA has been tested in two
independent sets of experiments at different doses and adminis-
tration frequencies, as indicated. The effects of the molecule on the
survival time of the mice and their statistical significance are
summarized in Table 1. In both experiments, GA reproducibly
induced a modest but statistically significant increase of the
survival time of treated mice as compared to the solvent-treated
mice (,6%) when the drug was administered once or twice a week
at 20 mg/kg. Increasing the number of treatments to three times a
week, although at a lower dose (4 mg/kg) appeared more
beneficial as survival time was increased by 19%, a percentage
approaching that observed with dextran sulfate 500 (DS500;
+26%), one of the best known anti-scrapie molecule because of its
known inhibitory effects on scrapie primo-replication in the spleen
of intraperitoneally-infected mice (see below and [29,31]).
Although the statistical significance of the difference observed
between the two types of regimen is borderline (p=0.06 Mann-
Whitney U test), this result suggests that a more frequent treatment
even with a lower dose could be at minima as efficient, in good
agreement with the short half-life of GA in vivo, i.e. a couple of
hours in the human body [23]. At terminal stage of the disease,
GA has no significant effects on brain PrP
Sc accumulation as
compared to solvent-treated mice (data not shown). In both
experiments, triplicates of mice were also euthanized when still
healthy at mid-infection (,50 days) to assess GA effects on spleen
PrP
Sc accumulation, a rapid method to identify drugs with any
anti-prion potential [29]. In the first experiment, GA slightly
inhibited PrP
res accumulation, although much less than DS500
(Figure 4a). However, quantification of the Western blot signals
and comparison with solvent-treated animals failed to demonstrate
any statistically significant effect of GA (Figure 4a). In the second
experiment, no significant effects were observed, whatever the
regimen administered (Figure 4b). Similar results were found at
terminal stage of disease in this tissue (data not shown). This
inconsistent inhibition of PrP
res accumulation in the spleen was
reminiscent of that observed previously with MS-8209, an
amphotericin B derivative [29] and suggests that GA does not
act through inhibition of PrP
Sc accumulation in spleen.
Overall, we have shown in two independent experiments a
significant effect of GA on the survival time of mice, in a model
that might be difficult to cure, due to the high infectious load
inoculated. We might anticipate that GA effects could be more
pronounced in a less stringent model [32].
Discussion
Taken together, our results indicate that GA, a drug already
used in clinic for the treatment of hypertension [23], is active in vivo
against both yeast and ovine prions. The data concerning the
activity of GA against PrP
Sc were obtained in ovinized transgenic
mouse and cell line models infected with sheep scrapie. It will be of
interest to determine the potential of this molecule in other prions
strains/species combinations, particularly humanized transgenic
Figure 2. Guanabenz efficiently promotes ovine PrP
Sc clear-
ance in an ex vivo cell-based assay. Scrapie-infected MovS6 cells
were treated for six days with the indicated concentrations of TA (panel
a) or GA (panel b, upper gel) and then lysed. Their effects on PrP
Sc
accumulation were determined by Western blot analysis using an anti-
PrP antibody. At the tested range of concentration, only GA was able to
promote PrP
Sc clearance. The effect of GA on the steady-state level of
PrP
C was determined in uninfected MovS6 cells (b lower gel). (c) Cell
lysates of untreated scrapie-infected MovS6 cells were directly
incubated with the indicated concentrations of GA or, as controls to
the corresponding quantity of DMSO, the compound vehicle. PrP
Sc was
then detected by Western blot analysis using an anti-PrP antibody.
Molecular weights (MW, in kilodaltons) are indicated to the right of the
blots.
doi:10.1371/journal.pone.0001981.g002
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Jakob types [33–36]. Nevertheless, because GA does not seem to
act directly on the PrP conversion process and because it is active
against both yeast and ovine prions which are not related both in
term of sequence and function, we believe this drug acts on
common prion controlling mechanisms conserved in eukaryotes.
Therefore our data suggest a potential new therapeutic indication
for GA in the treatment of prion-based disease in mammals,
including in humans. Indeed, GA has already been used safely in
clinic for almost 25 years without any major side-effects and its
pharmacology and toxicology are very well characterized. In
addition, as an antihypertensive drug whose mechanism of action
is an agonistic stimulatory effect of the central alpha-2 adrenergic
receptors in the cardiovascular regulatory centers in the brainstem
and spinal cord, GA is able to cross the blood brain barrier
[37,38]. We thus believe that GA could be evaluated in
compassionate treatments for human prion-based disease. This is
particularly appealing when one considers that quinacrine (QC)
and chlorpromazine (CPZ), two compounds already in clinic for a
long time for other applications and recently tested in human for
compassionate treatment of CJD, were totally inefficient in human
as well as in a mouse model similar to the one we used [25,26],
even in combination. Furthermore, these two molecules exhibit
severe side-effects which contrast with GA [23], which has been
Figure 3. Activity of chemical derivatives of GA. a. The same quantity (5 ml of 5 mM solutions) of GA and of six chemical derivatives was
spotted on filters as described in Figure 1. Note the lack of activity of GA analogs against [PSI+] yeast prion (upper right panel): for each of them, one
of the two chlorines present in GA is missing (PSI 136, 137, 140, 208 and GAi). In contrast, adding one additional chlorine significantly increases the
activity of the drug (GAh). GA, GAi and GAh were then tested for their ability to promote PrP
Sc clearance in the MovS6 cell-based system described
above. Molecular weights (MW, in kilodaltons) are indicated on the right of the blots. b. Four other antihypertensive and/or known agonists or
antagonists of a1- or a2-adrenergic receptors were tested against both [PSI+] and [URE3] yeast prions (top right) and mammalian prion using the
MovS6 cell-based assay (bottom right).
doi:10.1371/journal.pone.0001981.g003
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Interestingly, both QC and CPZ are only weakly active in the yeast-
based assay, which contrasts with GA. Moreover CPZ was not able
to prevent PrP
Sc accumulation in primary cultures of tg338 mouse
neurons infected with 127S scrapie strain [39]. It seems therefore
reasonable to suggest that CPZ may be inefficient in prolonging the
survival time of tg338 mice infected with this strain which is the one
used inour study. The yeast-based assaycould thushavea predictive
value of the in vivo activity of antiprion drugs isolated in cell-based
systems, especially since 6AP, another compound isolated as strongly
active in the yeast based assay [16], exhibited some activity in vivo in
the tg338 mouse model used in this study (VB and DV, unpublished
data). Concerning TA, its inactivity in the MovS6 cell-based assay
compared to the yeast-based system can have several explanations.
Among them are trivial issues such as differences in cell permeability
or in stability between the two systems. On the other hand it is well
possible that TA targets a yeast cellular pathway that is either absent
in mammals or that is too divergent to be efficiently targeted by this
drug. Finally, GA also represents a good chemical scaffold to identify
new potent antiprion molecules. The GAh derivative presented in
this paper constitutes a good example. Compared to GA, these new
compoundshavenotthe advantage to be alreadyinclinicbut,onthe
other hand, they could have no effect on hypertension, a side-effect
which could limit the use of GA as a treatment for prion based-
diseases in human and animals. Therefore it will be important to
determine the hypotensive and adrenergic receptorbinding activities
of GA derivatives for future use in anti-prion therapy.
Materials and Methods
Yeast strains and culture media
Yeast strains used in this study were as follows. Strg6: Mata,
erg6::TRP1, ade1-14, trp1-289, his3D200, ura3-52, leu2-3,112, [PSI+]
and SB34: Mata, erg6::TRP1, dal5::ADE2, ade2-1, trp1-1, leu2-3,112,
his3-11,15, ura2::HIS, [URE3] and were grown as previously
described [16,17].
Yeast-based antiprion screening assay
This assay was done as previously described [16,17]. Briefly,
yeast cells containing either [PSI+] or [URE3] prion lead to the
formation of white colonies on rich (YPD) medium whereas, once
cured of these prions ([psi2] or [ure3-0] cells), they lead to the
formation of red colonies, due to the accumulation of a metabolic
byproduct of the adenine biosynthesis pathway. An aliquot (350 ml
of an 0.5 OD600 overnight culture) of [PSI+] or [URE3] cells
(which grow as white colonies) were spread using sterile glass beads
on square (12 cm612 cm) Petri plates containing YPD medium
supplemented with 200 mM Guanidine hydrochloride (-GuHCl-
conditions where the sensitivity of the method is optimal). Sterile
small filters (similar to the ones used for antibiograms) were then
placed on the agar surface and individual compounds from the
Prestwick chemical libraryH (5 ml of 2 mg/ml solutions) were
applied to each filter, except for the top left filter where 5 mlo f
DMSO, the compounds vehicle was added (negative control) and
for the bottom right filter where 5 ml of a 300 mM GuHCl
solution in DMSO was added (positive control: GuHCl is a
chemical inhibitor of Hsp104p, a protein chaperone essential for
yeast prions propagation). The Petri plates were then incubated
three days at 25uC. When a compound is active against [PSI+]o r
[URE3] prions, a halo of red colonies appear around the filter
where it was spotted whereas colonies remain white in case of
inactive compounds. The brown halos appearing around some of
the filters are due to toxicity of the compounds deposited onto
these filters which, by preventing yeast cell growth and therefore
appearance of a lawn of yeast colonies (either as white or red
colonies) reveals the brown/orange colour of the YPD medium.
To confirm that potentially active compounds really cure yeast
prions and do not act against the colorimetric system used as a
reporter, cells from the red halos were streaked on a fresh drug-
free YPD medium to control that they still form red colonies, an
indication that [PSI+] or [URE3] prions were actually cured in
these cells [17].
PrP
Sc inhibition assay in MovS6 cells
Experiments were done as previously described [14]. Briefly,
MovS6 cells chronically infected with 127S strain were treated for
six days with the indicated concentrations of GA and then lysed.
Cell lysates were then subjected to proteinase K digestion (only
PrP
Sc is resistant to proteinase K) followed by Western blot
analysis using the Sha31 anti-PrP antibody [40]. Western blot
Table 1. Effect of guanabenz acetate (GA) on the survival time of transgenic mice expressing ovine PrP (tg338 line)
intraperitoneally inoculated with 127S scrapie strain.
Treatment (n/n0)
a Mean survival time Delay Significance p value
b
Number
c (mg/kg) Frequency/week (days6SEM) (days) (Mann-Whitney U test)
1
st experiment
Solvent
d 13 - 1 9/9 9661N A
e
DS 500 13 20 1 10/10 121632 5 ,0.0001
GA 20 20 2 then 1
f 9/9 10262 6 0.022
2
nd experiment
Solvent 13 - 1 6/6 9561N A
GA 13 20 1 9/9 10161 6 0.0005
GA 39 4 3 10/10 113611 18 0.0004
adiseased, PrP
Sc positive/inoculated mice.
bComparison tested: drug treatment to solvent.
cTotal number of treatments (see Methods).
d5% glucose.
eNA: not applicable.
f26per week for 50 days then 16per week.
doi:10.1371/journal.pone.0001981.t001
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sham) using a Vilber-Lourmat Photodocumentation Chemistart
5000 imager which allow precise quantification of the signals.
Effect of GA on the steady-state level of PrP
C
Uninfected MovS6 cells were treated for six days with the
indicated concentrations of GA and then lysed. Cell lysates were
analyzed by Western blot using the Sha31 anti-PrP antibody [40]
therefore allowing to determine potential effect of GA on the
expression of ovine Prnp gene in MovS6 cells. Western blot were
analyzed as mentioned above.
Analysis of GA potential direct effect on PrP
Sc aggregates
Cell lysates of untreated scrapie-infected MovS6 cells (127S
strain) were subjected directly to the indicated concentration of
GA (final concentration) for 5 hours at 25uC or, as control, to the
corresponding quantity of DMSO, the compound vehicle. They
were then subjected to proteinase K digestion followed by Western
blotting analysis using the Sha31 anti-PrP antibody [40]. Western
blot were analyzed as mentioned above.
Mouse model for prion-based disease
Experiments were done as previously described [41]. Mice
overexpressing ovine PrP (tg338 line [24]) were infected
intraperitoneally with 100 ml of the 127S scrapie strain at 0.02%
(w/v) dose. This strain has an intracerebral infectious titre of ,10
9
ID50 U/g of brain [14]. Mice were then treated with GA the day
following inoculation to exclude any direct interaction of the drug
with the inoculum injected. The treatment was stopped around 85
days post-infection, a few days before the first symptoms appeared
in the control mice group (mice treated with 5% glucose (solvent))
and the survival time in the different groups was determined. GA
has been tested in two independent sets of experiments. In the first
one, a 20 mg/kg dose of GA was intraperitoneally injected twice a
week up to 50 days post-infection and then once a week, for a total
of 20 treatments and a cumulative dose of 400 mg/kg. Its effects
were compared to those of a 20 mg/kg dose of dextran sulphate
500 (DS500), intraperitoneally injected once a week (13 treat-
ments, total dose 260 mg/kg). In the second set of experiments,
GA was injected once a week at 20 mg/kg (13 treatments, total
dose 260 mg/kg) or three times a week at 4 mg/kg (39 treatments,
total dose 156 mg/kg). Mice were euthanized at terminal stage.
Brains and spleens were collected and kept at 280uC for PrP
Sc
analysis. In both experiments, some mice were also euthanized
when still healthy in triplicates at 50 days post-inoculation to assess
the effects of GA on spleen PrP
Sc accumulation. Brains and spleens
tissues were homogenized at 20% (w/v) in 5% glucose with a
Rybolyser (Hybaid). PrP
res was extracted according to the Biorad
test protocol, by using 200 mg/ml proteinase K (Euromedex) for
10 min. at 37uC. After denaturation in Laemmli buffer, the
Figure 4. Effects of GA on PrP
Sc accumulation in scrapie-
infected mouse spleens at mid-incubation. Transgenic mice
overexpressing ovine PrP (tg338 line) were intraperitoneally infected
with scrapie (127S strain) and treated with GA by the same route. Two
independent experiments (shown respectively in panels a and b) have
been performed, in which the dose and overall number of treatments
varied, as indicated. Dextran Sulfate 500 (DS500, a) or GA solvent alone
(5% glucose, a and b) served as positive and negative controls,
respectively. In each treated group, triplicates of healthy mice were
euthanized ,50 days post-infection and the rate of PrP
Sc detectable in
their spleens was determined by Western blot (see Materials and
Methods). The same amount of spleen tissue material has been loaded
on the gels. For each triplicate, Western blot of spleen PrP
Sc and
densitometric quantification are shown. Each dot of the graph
represents the PrP
Sc content of a single spleen. The dark horizontal
line is the mean value. Statistical significance (p) was assessed using the
non-parametric Kruskal-Wallis test. ns: not significant. Note that GA did
not significantly affect spleen PrP
Sc level, although it showed a
beneficial effect on mouse survival in both sets of independent
experiments (see Table 1).
doi:10.1371/journal.pone.0001981.g004
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transferred onto nitrocellulose membranes and immunoblotted
with 0.1 mg/ml anti-PrP antibody Sha31 [40]. The equivalent of
1 mg of spleen and 0.5 mg of brain tissue was loaded onto the gels.
Immunoreactivity was visualized by chemiluminescence (GE
Healthcare). The optical density of each sample (i.e. the three
PrP
res glycoforms) was determined by the GeneTools software
after acquisition of chemiluminescent signal with a GeneGnome
digital imager (Syngene).
Chemical compounds
Prestwick Chemical LibraryH was purchased from Prestwick
Chemical company (Illkirch, France). It consists of a collection of
880 molecules, 90% being marketed drugs and 10% bioactive
alkaloids or related substances, thus representing a high degree of
drug-likeness. According to the manufacturer, the active com-
pounds were selected for their high chemical and pharmacological
diversity as well as for their known bioavailability and safety in
humans. The compounds were supplied in 96-wells plates as
2 mg/ml solution in DMSO (approximatively 5 mM depending
on the exact molecular weight (MW) of the considered
compounds). GA, TA, Clonidine, Cirazoline, Rilmenidine,
Efaroxan and GuHCl were purchased from Sigma.
Synthesis of GA derivatives
Synthesis of all these compounds (GAh, GAi, PSI136, PSI137,
PSI140 and PSI208) and of GA itself will be described elsewhere
(FG, MB and HG, in preparation). Purity of all these molecules
was determined using NMR, IR, mass spectrometry (MS) and
HPLC and details can be given upon request.
Supporting Information
Figure S1 Quinacrine and Chlorpromazine are only weakly
active against yeast prions. a. An aliquot of an overnight culture of
a [PSI+] Strg6 strain (which grows as white colonies) was spread
on Petri plates containing rich YPD (as indicated in the Materials
and Methods section). Small filters (similar to the ones used for
antibiograms) were then placed on the agar surface and individual
compounds from the Prestwick chemical libraryH (5 ml of 2 mg/ml
solutions) were applied to each filter, except for the top left filter
where DMSO, the compounds vehicle was added (negative
control) and for the bottom right filter where 5 ml of a 300 mM
GuHCl solution in DMSO was added (positive control). The Petri
plates were then incubated three days at 25uC. When a compound
was active against [PSI+], a halo of red colonies appeared around
the filter where it was spotted. Petri plate where Quinacrine (QC,
left) and Chlorpromazine (CPZ, right) were spotted is shown. The
molecular structures of QC and of CPZ are depicted on the top of
the Petri plate. The red halos corresponding to QC- or CPZ-cured
cells are indicated by arrows. Brown halos correspond to toxic
compounds (see Materials and Methods).
Found at: doi:10.1371/journal.pone.0001981.s001 (2.51 MB TIF)
Figure S2 hydroxy Tacrine is moderately active against yeast
prions and inactive to promote ovine PrPSc clearance in an ex
vivo cell-based assay a. The same plate than in Figure 1a is shown
and the position where hydroxy Tacrine (hTA) was loaded is
indicated by an arrow. The molecular structure of hTA is depicted
on the top right of the Petri plate. b. Scrapie-infected MovS6 cells
were treated for six days with the indicated concentrations of hTA
and then lysed. PrPSc levels were determined by Western blot
analysis using an anti-PrP antibody. At the tested range of
concentration, hTA, as TA, was unable to promote PrPSc
clearance. Molecular weights (MW, in kilodaltons) are indicated
to the right of the blot.
Found at: doi:10.1371/journal.pone.0001981.s002 (2.83 MB TIF)
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